August 21, 2014 12:56 PM ET

Pharmaceuticals

Company Overview of MyoKardia, Inc.

Company Overview

MyoKardia, Inc. develops a pipeline of small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The company was founded in 2012 and is based in San Francisco, California.

455 Mission Bay Boulevard South

Suite 575

San Francisco, CA 94158

United States

Founded in 2012

Phone:

415-766-3641

Key Executives for MyoKardia, Inc.

Chief Executive Officer and Director
Co-Founder
Co-Founder
Age: 72
Compensation as of Fiscal Year 2014.

MyoKardia, Inc. Key Developments

MyoKardia, Inc Appoints Mark L. Perry to Board of Directors

MyoKardia, Inc. announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr. Mr. Perry currently serves as chairman of the board of Pathway Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.

MyoKardia, Inc. Announces Management Changes

MyoKardia, Inc. announced the appointment of Tassos Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO Charles Homcy, M.D., who will remain on MyoKardia's board of directors. Mr. Gianakakos brings more than 17 years of broad-based biopharmaceutical expertise to MyoKardia. He joins the company from MAP Pharmaceuticals, where he was most recently senior vice president and chief business officer.

MyoKardia, Inc. Appoints Jonathan C. Fox, M.D., Ph.D., as Chief Medical Officer

MyoKardia, Inc. announced the appointment of Jonathan C. Fox, M.D., Ph.D., as Chief Medical Officer. In his role, Dr. Fox will be responsible for the clinical development and regulatory strategy for MyoKardia's pipeline of novel, small molecule therapeutics focused on treatments for genetically determined hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Dr. Fox brings to MyoKardia working knowledge across all phases of clinical development, from clinical pharmacology to large cardiovascular outcomes trials. In his previous roles with top tier global biopharmaceutical companies, Dr. Fox led clinical research teams that secured multiple cardiometabolic drug product approvals. Before joining MyoKardia, he served as Vice President of Clinical Development at AstraZeneca; Senior Director, Clinical Cardiovascular Research at Merck; and Director of Clinical Pharmacology at SmithKline Beecham.

Similar Private Companies By Industry

Company Name Region
Altheus Therapeutics, Inc. United States
Altor BioScience Corporation United States
Nutricetical Solutions, Inc. United States
Wellington Foods, Inc. United States
Revalesio Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MyoKardia, Inc., please visit www.myokardia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.